Bayer Counters Gen-Probe Arbitration Claims, Alleges NAT Development Delay
This article was originally published in The Gray Sheet
Executive Summary
Gen-Probe is assuring investors that commercial launch of its Tigris molecular diagnostic/nucleic acid testing instrument is forthcoming